S'abonner

Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis - 04/12/15

Doi : 10.1016/j.jaci.2015.05.034 
Tim Wiechers, MD a, , Anja Rabenhorst, PhD a, , Tina Schick, MD a, b, Liane M. Preussner, MD a, Anja Förster, PhD a, Peter Valent, MD c, Hans-Peter Horny, MD d, Karl Sotlar, MD d, Karin Hartmann, MD a, e,
a Department of Dermatology, University of Cologne, Cologne, Germany 
b Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany 
c Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria 
d Institute of Pathology, Ludwig-Maximilians-Universität, Munich, Germany 
e Department of Dermatology, University of Luebeck, Luebeck, Germany 

Corresponding author: Karin Hartmann, MD, Department of Dermatology, University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany.

Abstract

Background

Mastocytosis, characterized by pathologic accumulation of mast cells, can manifest itself in adulthood or childhood. Pediatric patients usually have cutaneous mastocytosis (CM) with mast cell infiltrates limited to the skin and spontaneous improvement of skin lesions after several years. However, there are some patients with persistent disease resembling adulthood-onset mastocytosis.

Objective

The current classification of CM differentiates between 3 subforms. In clinical practice we noticed that different variants of these subforms might exist, particularly in patients with childhood-onset mastocytosis. Therefore, in the present study, we aimed to investigate whether specific cutaneous lesions in patients with childhood-onset mastocytosis are associated with other disease parameters.

Methods

We analyzed 144 patients with a disease onset of less than age 17 years using a systematic dermatologic approach.

Results

One hundred twenty-two patients presented with maculopapular cutaneous mastocytosis (MPCM), 12 patients presented with diffuse CM, and 10 patients presented with solitary mastocytoma of the skin. Patients with MPCM showed particularly heterogeneous cutaneous lesions and were therefore grouped into 3 variants presenting either with small lesions (MPCM-small, skin lesions <1 cm in diameter; n = 19), large lesions (MPCM-large, skin lesions ≥1 cm in diameter; n = 89), or atypical lesions (MPCM-other, n = 14). Patients with MPCM-large lesions, compared with those with MPCM-small lesions, were characterized by significantly lower tryptase levels, shorter disease duration, and earlier disease onset. In addition, more patients with MPCM-large lesions exhibited spontaneous regression of cutaneous lesions.

Conclusion

Our data show that patients with MPCM-large lesions compared with those with MPCM-small lesions have a more favorable disease course and suggest exploring the size of cutaneous lesions as a prognostic parameter in childhood-onset MPCM.

Le texte complet de cet article est disponible en PDF.

Key words : Childhood-onset mastocytosis, cutaneous mastocytosis, KIT mutation, mast cell, mastocytosis, pediatric mastocytosis, prognosis, skin, tryptase, urticaria pigmentosa

Abbreviations used : CM, DCM, MC, MPCM, SM


Plan


 Supported by a research grant from the German Research Council (HA 2393/6-1; to K.H.).
 Disclosure of potential conflict of interest: T. Wiechers is employed by Krankenhaus Porz am Rhein. T. Schick has received lecture fees from Novartis Pharma. P. Valent has received consultancy fees, research support, and travel support from Novartis and has received lecture fees from Novartis, Ariad, and Pfizer. H.-P. Horny has received consultancy fees from Novartis. K. Sotlar has received lecture fees from Nanostring and has received travel support from Novartis. K. Hartmann has received consultancy fees from Novartis and has received lecture fees from ALK-Abelló, Novartis, and Shire. The rest of the authors declare that they have no relevant conflicts of interest.


© 2015  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 136 - N° 6

P. 1581 - décembre 2015 Retour au numéro
Article précédent Article précédent
  • Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis
  • Christoph Riethmuller, Maeve A. McAleer, Sjors A. Koppes, Rawad Abdayem, Jonas Franz, Marek Haftek, Linda E. Campbell, Stephanie F. MacCallum, W.H. Irwin McLean, Alan D. Irvine, Sanja Kezic
| Article suivant Article suivant
  • Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum
  • Li Gao, Lianghua Bin, Nicholas M. Rafaels, Lili Huang, Joseph Potee, Ingo Ruczinski, Terri H. Beaty, Amy S. Paller, Lynda C. Schneider, Rich Gallo, Jon M. Hanifin, Lisa A. Beck, Raif S. Geha, Rasika A. Mathias, Kathleen C. Barnes, Donald Y.M. Leung

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.